A randomized controlled open comparative trial of varenicline vs nicotine patch in adult smokers: Efficacy, safety and withdrawal symptoms (the VN-SEESAW study)

Circulation Journal

Volumn 74, Issue 4, 2010, Pages 771-778

  Tsukahara, Hitomi ^a   Noda, Keita ^a   Saku, Keijiro ^b  

^a FUKUOKA UNIVERSITY   (Japan)

^b FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Comparative trial; Nicotine patch; Smoking abstinence rates; Varenicline; Withdrawal symptoms

Indexed keywords

NICOTINE PATCH; TOBACCO SMOKE; VARENICLINE;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION LOSS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ECG ABNORMALITY; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; INSOMNIA; JAPANESE; MALE; MENTAL DISEASE; NAUSEA; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SELF MONITORING; SIDE EFFECT; SKIN ALLERGY; SLEEP DEPRIVATION; SMOKING CESSATION; SMOKING HABIT; STRESS; TOBACCO DEPENDENCE; TREATMENT DURATION; TREATMENT RESPONSE; WITHDRAWAL SYNDROME;

ADMINISTRATION, CUTANEOUS; ADULT; BENZAZEPINES; EMOTIONS; ENDPOINT DETERMINATION; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NICOTINE; NICOTINIC AGONISTS; QUINOXALINES; RISK FACTORS; SMOKING; SMOKING CESSATION; STRESS, PSYCHOLOGICAL; SUBSTANCE WITHDRAWAL SYNDROME; TREATMENT OUTCOME;

EID: 77950667776     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-09-0803     Document Type: Article

References (18)

1. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: Systematic analysis of population health data. Lancet 2006; 367: 1747-1757.
2. World Health Organization. Report on the Global Tobacco Epidemic, 2008: The MPOWER package. http://www.who.int/tobacco/mpower/en/ (available at December 30, 2008)
3. Japanese Ministry of Health, Labor and Welfare. Smoking topics. http://www.mhlw.go.jp/topics/tobacco/toukei/kituen03.html (available at December 30, 2007)
4. Maskos U, Molles BE, Pons S, Besson M, Guiard BP, Guilloux JP, et al. Nicotine reinforcement and cognition restored by targeted expression of nicotinic receptors. Nature 2005; 436: 103-107.
5. Coe JW, Brooks PR, Vetelino MG, Wirtz MC, Arnold EP, Huang J, et al. Varenicline: An α4β2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 2005; 48: 3474-3477.
6. Rollema H, Chambers LK, Coe JW, Glowa J, Hurst RS, Lebel LA, et al. Pharmacological profile of the α4β2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology 2007; 52: 985-994.
7. Kassel JD, Stroud LR, Paronis CA. Smoking, stress, and negative affect: Correlation, causation, and context across stages of smoking. Psychol Bull 2003; 129: 270-304.
8. Stevens SL, Colwell B, Smith DW, Robinson J, McMillan C. An exploration of self-reported negative affect by adolescents as a reason for smoking: Implications for tobacco prevention and intervention programs. Prev Med 2005; 41: 589-596.
9. Japanese Society of Circulation, The Japan Lung Cancer Society, Japan Cancer Association. 3rd manual of anti-smoking therapy in Japan, 2008.
10. Nakamura M, Oshima A, Fujimoto Y, Maruyama N, Ishibashi T, Reeves KR. Efficacy and tolerability of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week followup for smoking cessation in Japanese smokers. Clin Ther 2007; 29: 1040-1056.
11. Kuehn BM. Varenicline gets stronger warnings about psychiatric problems, vehicle crashes. JAMA 2009; 302: 834.
12. Aubin HJ, Bobak A, Britton JR, Oncken C, Billing CB Jr, Gong J, et al. Varenicline versus transdermal nicotine patch for smoking cessation: Results from a randomised open-label trial. Thorax 2008; 63: 717-724.
13. Stapleton JA, Watson L, Spirling LI, Smith R, Milbrandt A, Ratcliffe M, et al. Varenicline in the routine treatment of tobacco dependence: A pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness. Addiction 2008; 103: 146-154.
14. Higashiyama A, Okamura T, Ono Y, Watanabe M, Kokubo Y, Okayama A. Risk of smoking and metabolic syndrome for incidence of cardiovascular disease: Comparison of relative contribution in urban Japanese population: The Suita study. Circ J 2009; 73: 2258-2263.
15. Yufu K, Takahashi N, Okada N, Shinohara T, Hara M, Saikawa T, et al. Influence of systolic blood pressure and cigarette smoking on endothelial function in young healthy people. Circ J 2009; 73: 174-178.
16. Hardoon SL, Whincup PH, Lennon LT, Wannamethee SG, Capewell S, Morris RW. How much of the recent decline in the incidence of myocardial infarction in British men can be explained by changes in cardiovascular risk factors? Evidence from a prospective population-based study. Circulation 2008; 117: 598-604.
17. Lightwood JM, Glantz SA. Short-term economic and health benefits of smoking cessation: Myocardial infarction and stroke. Circulation 1997; 96: 1089-1096.
18. Reid RD, Quinlan B, Riley DL, Pipe AL. Smoking cessation: Lessons learned from clinical trial evidence. Curr Opin Cardiol 2007; 22: 280-285.